Brief: Ascletis Pharma Inc Says Third-Party Petition Filed Against Company's U.S. Patent
30/06/2025 02:46
June 30 (Reuters) - Ascletis Pharma Inc 1672.HK: THIRD-PARTY PETITION FILED AGAINST COMPANY'S U.S. PATENT BECOME AWARE OF PETITION FOR POST GRANT REVIEW FILED WITH UNITED STATES PATENT AND TRADEMARK OFFICE BY CONJUPRO BIOTHERAPEUTICS PETITION CHALLENGED VALIDITY OF CLAIMS OF GRANTED U.S. PATENT NO. 12,234,236 OWNED BY ASCLETIS PHARMA (CHINA) CO PETITION REMAINS UNDER REVIEW BY USPTO AS AT JUNE 30 Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management